CN Patent

CN106749226B — 一种avatrombopag马来酸盐晶型C的制备方法

Assigned to Shandong Haoruien Pharmaceutical Co ltd · Expires 2019-12-20 · 6y expired

What this patent protects

本发明公开了一种avatrombopag马来酸盐晶型C的制备方法，其包括以下步骤：1)将avatrombopag马来酸盐溶解在DMF中，加入avatrombopag马来酸盐的不良溶剂，在小于60℃下搅拌；2)控制温度在小于40℃下，搅拌析晶，过滤，得白色固体；3)干燥所述白色固体，即得avatrombopag马来酸盐晶型C。本发明的方法制得的avatrombopag马来酸盐晶型C收率和纯度较高，操作简单，适合工业化生产。

USPTO Abstract

本发明公开了一种avatrombopag马来酸盐晶型C的制备方法，其包括以下步骤：1)将avatrombopag马来酸盐溶解在DMF中，加入avatrombopag马来酸盐的不良溶剂，在小于60℃下搅拌；2)控制温度在小于40℃下，搅拌析晶，过滤，得白色固体；3)干燥所述白色固体，即得avatrombopag马来酸盐晶型C。本发明的方法制得的avatrombopag马来酸盐晶型C收率和纯度较高，操作简单，适合工业化生产。

Drugs covered by this patent

Patent Metadata

Patent number
CN106749226B
Jurisdiction
CN
Classification
—
Expires
2019-12-20
Drug substance claim
No
Drug product claim
No
Assignee
Shandong Haoruien Pharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.